Table 1. Patient and product characteristics.
Median (n = 10)Range
Age59.545–76
Sex (male)50%
Time from initial diagnosis to
infusion (in days)
358179–682
Line of treatment at infusion
  220%
  340%
  440%
Karnofsky performance status
  10020%
  9030%
  8030%
  7010%
  6010%
Receiving steroids at infusion20%
EGFRvIII expression71%(6–96%)
% T cells transduced19.75%(4.8–25.6%)
Dose of CART-EGFRvIII5 × 108(1.75 × 108–5 × 108)